Ceramic On Ceramic (COC) 36mm PAS IDE Rollover Subjects; Ceramic Acetabular Bearing With Ceramic Femoral Head in Total Hip Replacement
Launched by DEPUY ORTHOPAEDICS · Mar 21, 2014
Trial Information
Current as of June 03, 2025
Completed
Keywords
ClinConnect Summary
Up to five (5) sites will participate. These sites participated in the IDE study and will continue subject follow-up.
Subjects from the original IDE study (COC 36mm investigational subjects only) will be seen for a clinic visit at the time of consent (First visit at approximately 5 to 7 years post-op or 1825- 2919 days), and at minimum 8 years (2920-3649 days) , and minimum 10 years (3650-4015 days). Harris Hip evaluation, radiographic evaluation, subject hip-outcomes, and adverse event information will be collected at each visit.
If a subject is not willing or able to return for a clinic...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects who were previously enrolled in the COC 36 IDE study;
- • Individuals who are willing and able to provide informed patient consent for participation in the study;
- • Individuals who are willing and able to return for follow-up as specified by the study protocol; and
- • Individuals who are willing and able to complete the Subject Hip Outcomes questionnaire as specified by the study protocol.
- Exclusion Criteria:
- • In the opinion of the Investigator, the individual does not qualify if there are any concerns with the ability to follow the protocol specified evaluations.
- • Any component of the primary total hip was previously revised.
About Depuy Orthopaedics
DePuy Orthopaedics, a subsidiary of Johnson & Johnson, is a leading global provider of orthopedic medical devices, specializing in the development, manufacturing, and marketing of innovative solutions for joint reconstruction, trauma, and spinal care. With a commitment to advancing patient outcomes through cutting-edge technology and evidence-based practices, DePuy Orthopaedics actively engages in clinical trials to evaluate the safety and efficacy of its products. The company collaborates with healthcare professionals and institutions to ensure that its offerings meet the highest standards of quality and effectiveness, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Denver, Colorado, United States
Winston Salem, North Carolina, United States
Sacramento, California, United States
Alexandria, Virginia, United States
Winston Salem, North Carolina, United States
Columbus, Ohio, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials